UnknownNot Applicable

MISOPROSTOL FOR THE TREATMENT OF SUSPECTED POSTPARTUM RETAINED PRODUCTS OF CONCEPTION

Israel150 participantsStarted 2021-02-02

Plain-language summary

The goal of this current study is to evaluate the efficacy of treatment of postpartum patients with suspected retained products of conception (RPOC) with Misoprostol in reducing the frequency of postpartum RPOC compared to a control group of patients that will be managed expectantly, in a prospective randomized trial.

Who can participate

Age range18 Years – 45 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Women between the ages of 18 years - 45 years. * Spontaneous vaginal delivery or vacuum extraction, including VBAC cases * Revision of the uterine cavity or manual lysis of the placenta postpartum * Early postpartum hemorrhage * Cases with a history of treated postpartum residua (by curettage or hysteroscopy) * Placental pathology (succenturiate placenta, bilobed placenta) * Pregnancy that started as a multifetal gestation with only one fetus reached advanced pregnancy * Bumm curettage post-delivery * Patients are able to provide written consent Exclusion Criteria: * Patients with no risk factors of RPOC * Cesarean section on index pregnancy * Cases requiring urgent curettage for late postpartum hemorrhage * Inability to consent due to cognitive or language barrier

What they're measuring

Cases of retained products of conception

Timeframe: 8-16 weeks postpartum

Trial details

NCT IDNCT06009679

SponsorAssuta Ashdod Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-12-31

Contact for this trial

oshri Barel, MD

+972559382117 oshrib@assuta.co.il

View on ClinicalTrials.gov More Retained Products of Conception trials